Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Total positions of BlackRock, Inc. and its funds subject to notification:ORION CORPORATION
STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS
25 APRIL 2024 at 16.30 EEST
獵戶座公司
證券交易所新聞稿—主要股東公告
2024 年 4 月 25 日美國東部標準時間 16:30
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
獵戶座公司：根據《證券市場法》第9章第10節進行披露（貝萊德公司）
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2024 above five (5) per cent of Orion Corporation's total shares.
獵戶座公司已根據《證券市場法》第9章第5款收到披露，根據該披露，貝萊德公司及其基金直接、間接和通過金融工具持有的獵戶座股份總數在2024年4月24日增加到獵戶座公司總股份的五（5）％以上。
Total positions of BlackRock, Inc. and its funds subject to notification:
貝萊德公司及其基金的總頭寸有待通知：
|
% of shares and voting rights (total of point A) |
% of shares and voting rights through financial instruments (total of point B) |
Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 4.99% shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
5.01% shares Below 5% voting rights |
141,134,278 shares 772,549,137 voting rights |
| Position of previous notification (if applicable) | Below 5% shares Below 5% voting rights |
Below 5% shares Below 5% voting rights |
Below 5% shares Below 5% voting rights |
| 股份和投票權的百分比 （A點的總和） |
通過金融工具獲得的股份和投票權的百分比 （B 點的總和） |
兩者的總和，以% 爲單位（點 A + B） | 發行人的股份總數和投票權 | |
| 在超過或達到閾值之日產生的情形 | 4.99% 的股份 投票權低於 5% |
0.02% 的股份 投票權低於 5% |
5.01% 股票 投票權低於 5% |
141,134,278 股 772,549,137 表決權 |
| 先前通知的位置（如果適用） | 低於 5% 的股份 投票權低於 5% |
低於 5% 的股份 投票權低於 5% |
低於 5% 的股份 投票權低於 5% |
Notified details of the resulting situation on the date on which the threshold was crossed:
已通報的有關跨越閾值之日所產生情況的詳細信息：
Point A: Shares and voting rights:
A點：股份和投票權：
|
Class/type of shares ISIN code |
Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 7,042,654 shares Below 5% voting rights |
4.99% shares Below 5% voting rights |
||
| POINT A SUBTOTAL | 7,042,654 shares Below 5% voting rights |
4.99% shares Below 5% voting rights |
||
| 股票類別/類型 ISIN 代碼 |
股份數量和投票權 | 股份和投票權的百分比 | ||
| 直接（SMA 9:5） | 間接（SMA 9:6 和 9:7） | 直接（SMA 9:5） | 間接（SMA 9:6 和 9:7） | |
| FI0009014377 | 7,042,654 股 投票權低於 5% |
4.99% 的股份 投票權低於 5% |
||
| 點一個小計 | 7,042,654 股 投票權低於 5% |
4.99% 的股份 投票權低於 5% |
||
Point B: Financial instruments according to SMA 9:6a:
B點：根據SMA 9:6 a的金融工具：
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Securities Lent | N/A | N/A | Physical | 34,596 shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
| CFD | N/A | N/A | Cash | 4,438 shares Below 5% voting rights |
0.00% shares Below 5% voting rights |
| POINT B SUBTOTAL | 39,034 shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
| 金融工具的類型 | 到期日期 | 運動/轉換期 | 實物結算或現金結算 | 股份數量和投票權 | 股份和投票權的百分比 |
| 借出的證券 | 不適用 | 不適用 | 物理 | 34,596 股 投票權低於 5% |
0.02% 的股份 投票權低於 5% |
| CFD | 不適用 | 不適用 | 現金 | 4,438 股 投票權低於 5% |
0.00% 的股份 投票權低於 5% |
| 第 B 點小計 | 39,034 股 投票權低於 5% |
0.02% 的股份 投票權低於 5% |
Orion Corporation
獵戶座公司
| Liisa Hurme President and CEO |
Olli Huotari SVP, Corporate Functions |
| Liisa Hurme 總裁兼首席執行官 |
Olli Huotari 企業職能高級副總裁 |
Contact person:
Tuukka Hirvonen, Investor Relations
聯繫人：
Tuukka Hirvonen，投資者關係
tel. +358 10 426 2721
電話：+358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
出版商：
獵戶座公司
通信
Orionintie 1A，FI-02200 埃斯波，芬蘭
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Orion 是一家全球運營的芬蘭製藥公司，是幸福的締造者。我們開發、製造和銷售人類和獸藥以及活性藥物成分。Orion 擁有廣泛的專有和仿製藥以及消費者健康產品組合。我們藥物研發的核心治療領域是腫瘤學和疼痛。Orion 開發的專有產品用於治療癌症、神經系統疾病和呼吸系統疾病等。獵戶座在2023年的淨銷售額爲11.9億歐元，截至年底，該公司擁有約3600名員工。獵戶座的A股和B股在赫爾辛基納斯達克上市。
